Desperately Seeking a Randomized Clinical Trial of Resynchronization Therapy for Patients With Heart Failure and Atrial Fibrillation⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by Steinberg, Jonathan S.
ED
R
R
P
A
J
N
T
fi
i
t
l
o
c
a
s
i
s
a
p
2
I
i
A
a
d
p
p
p
e
c
a
o
p
i
d
v
A
H
Y
s
W
I
Journal of the American College of Cardiology Vol. 48, No. 4, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Po
c
d
a
a
s
a
e
h
i
i
r
m
q
t
n
r
b
i
S
s
t
i
v
d
w
i
a
q
s
p
l
r
i
a
p
S
t
h
p
f
r
t
t
c
o
t
r
(
i
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.031DITORIAL COMMENT
esperately Seeking a
andomized Clinical Trial of
esynchronization Therapy for
atients With Heart Failure and
trial Fibrillation*
onathan S. Steinberg, MD, FACC
ew York, New York
he twin epidemics of modern cardiovascular disease, atrial
brillation (AF) and heart failure (HF), present terribly
mportant management challenges. When these 2 condi-
ions co-exist, an effective strategy to ameliorate symptoms,
imit hospitalization, and improve prognosis is a critical
bjective given their prevalence and clinical and economic
onsequences (1,2). Although much recent, even remark-
ble, progress has been made, there remain major clinical
ubgroups in which the application of new therapeutic tools
s still poorly defined.
See page 734
In the HF patient, the likelihood of co-existent AF is
trongly related to the underlying New York Heart Associ-
tion (NYHA) functional class. In approximate terms, the
revalence of AF is 5% for NYHA functional class I, 10% to
5% for class II to III, and as high as 50% for class IV (3).
n addition, for the HF patient in sinus rhythm, the annual
ncidence of AF is approximately 5%. The development of
F is difficult to predict (4), but risk is greatest in those with
trial conduction delay (5) or evidence of atrial mechanical
ysfunction (4), suggesting that an atrial myopathy accom-
anies the HF condition and paves the way for the electro-
hysiologic abnormalities that promote AF (6). Indeed,
athologic damage, including fibrosis, to the atria becomes
vident more quickly and more extensively than the ventri-
les in tachycardia models of HF (7,8) suggesting that the
trial myopathy of HF is an early and consistent component
f the HF condition. The development of AF in the HF
atient often heralds a worse prognosis (9,10). For example,
n the Framingham study, the risk of death approximately
oubled in HF patients who experienced AF (9).
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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nc., and Biotronik.Atrial fibrillation is generally associated with a nonphysi-
logic rapid ventricular rate, which in and of itself may
reate cardiomyopathy or aggravate underlying ventricular
ysfunction. Rate control thus becomes critically important,
nd medical therapy with beta-receptor antagonists is usu-
lly employed. Additional measures include digoxin and
ometimes amiodarone. Some patients may benefit from
trioventricular (AV) junctional ablation to permanently
liminate tachycardia by deliberately creating complete
eart block; rate is then controlled, and rhythm is regular-
zed via an implanted permanent pacemaker. This technique
s commonly known as “ablate and pace.” For patients with
efractory tachycardia despite medical therapy, or when
edications are poorly tolerated, this approach can improve
uality of life and ventricular function (11,12). Generally,
his invasive strategy has been reserved for the small
umbers of patients who meet stringent criteria because it
enders the patient pacemaker-dependent.
Cardiac resynchronization therapy (CRT) has recently
een introduced to correct ventricular dyssynchrony present
n many patients with bundle branch block and HF.
ubstantial laboratory and clinical experience preceded
mall- and large-scale clinical trials, and ultimately brought
his innovative technology to the clinic with established
ndications, namely NYHA functional class III to IV, left
entricular ejection fraction (LVEF) 35%, and QRS
uration120 to 130 ms. Interestingly, virtually all patients
ho participated in the clinical investigations of CRT were
n sinus rhythm, and there is precious little experience of
pplying CRT in patients with HF and AF.
Why does it matter if the patient who may otherwise
ualify for CRT has AF? Patients with AF have no AV
ynchrony, so coordinated AV pacing with appropriately
rogrammed AV intervals is not possible. Thus, biventricu-
ar pacing delivery, and more importantly capture, cannot be
eliably assured. Patients with AF often have consistent or
ntermittent excessive ventricular rates, necessitating pacing
t higher than desired programmed pacing rates, if indeed
acing can keep up with the underlying rate and pattern.
pecial pacing features can attempt to consistently overtake
he spontaneous rhythm, but may do so at the expense of
igher rates or may not be consistently effective. Even when
acing is delivered, many ventricular complexes may be
used or pseudo-fused, making pacing capture percentages
etrievable from the CRT device inaccurate and an overes-
imate of effective pacing capture. It is generally believed
hat near maximal effective and complete biventricular
apture is necessary to assure optimal CRT response.
Although CRT has now undergone rigorous and thor-
ugh investigation, only 1 randomized clinical trial permit-
ed enrollment of patients with AF, and all others were
estricted to patients in sinus rhythm. This trial, MUSTIC
Multisite Simulation in Cardiomyopathies), was a random-
zed crossover 6-month investigation; a substudy (13) en-
olled patients with NYHA functional class III heart failure,
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August 15, 2006:744–6 Editorial Commentjection fraction 35%, left ventricular end-diastolic diam-
ter 60 mm on echocardiogram, a right-ventricular-paced
RS duration 200 ms, persistent AF of at least 3 months
uration, and “a slow ventricular rate, either spontaneously
r induced by AV node radiofrequency ablation.” This latter
ntry criterion is important to emphasize because it distin-
uished a subset of patients with AF and HF who were
uch more likely to have a high degree of effective ventric-
lar capture. The study enrolled 64 patients, but ultimately
nly 39 completed both crossover phases, greatly hampering
he study’s impact. The intent-to-treat analysis found no
ignificant difference in the primary end point, the 6-min
alk test. Although this trial described some positive trends
n secondary end points and analyses, and other acute
emodynamic studies (14) or nonrandomized observational
eports (15,16) suggested benefit, the reality is that it is still
nclear if and to what degree CRT provides long-term
enefit to patients with AF and HF, and how to reliably
chieve the necessary rate control for CRT to be effective in
he setting of AF.
The paper by Gasparini et al. (17) published in this issue
f the Journal brings fresh and intriguing data to this void.
his unique report describes the outcome of over 600
rospectively followed patients treated with CRT at 2
uropean centers. Of the 114 patients with AF, a shock-
ngly low proportion, 42%, achieved “adequate” biventricu-
ar capture (arbitrarily defined as85% at 2 months) despite
he usual pharmacologic and pacing programming efforts.
hose who did not achieve adequate capture, by protocol
esign in a nonrandomized format, underwent AV junc-
ional ablation resulting in near complete biventricular
apture. Reassuringly, patients with AF and patients with
inus rhythm had similar benefits from CRT across multiple
elevant end points. But it is within the AF group that the
esults yielded compelling and provocative data. Only the
atients with AF who had undergone AV junctional abla-
ion demonstrated evidence of reverse remodeling (in-
reased LVEF, decreased left ventricular end-systolic vol-
me) and functional improvement. A substantial overall
esponse rate (about two-thirds) was seen in the ablated
atients, but a very poor response rate (20%) was observed
n the nonablated patients. The authors attributed this
eneficial response to the imposition of AV junctional
blation after CRT, resulting in predictable and consistent
00% ventricular capture versus the capture rate of 88% in
he group that did not undergo ablation.
Certainly this study’s outcomes and explanations are
lausible and logical. The ablation renders the patient
acemaker-dependent thus ensuring that CRT is perfectly,
ully, and consistently invoked without fusion or pseudo-
usion; inadequate rate control is removed from even an
ntermittent event, and the rhythm is regularized, imparting
hat additional benefit on ventricular performance (18). The
esults suggest that even relatively high percentage biven-
ricular capture may be inadequate, which has the practical
essage that all CRT patients should be regularly interro-ated to ensure close to 100% capture and, if not, to take
rudent measures to achieve this goal regardless of under-
ying rhythm.
This is an important large observational study, but the
esults must be interpreted cautiously. The study did not
andomly allocate the ablation therapy, and it is possible
hat the nonablated group differed in some important way
hat affected outcome. On the surface, there were no
mportant differences between the groups, but unmeasured
ariables certainly may have been discrepant. The relative
ontributions of better rate control and CRT in the ablated
roup could not be discerned. It is also conceivable that the
erceived need to perform ablation was triggered by fac-
or(s) that simply identified a group of patients who were
estined to respond to CRT regardless of the imposition of
blation. Although unlikely, continuation of drugs in the
onablated group to achieve rate control, which were not
eeded in the ablated group, may have unexpectedly influ-
nced some end points (19). The interrogation of ventric-
lar pacing percentage was performed only once and may
ave been inaccurate or unrepresentative. No data are
vailable regarding hospitalization and mortality. The fore-
oing discussion is most relevant to those with permanent
F; patients with paroxysmal AF or AF of shorter duration
ay have a rhythm control approach with appropriate drug
r ablation strategies. However, concern over long-term risk
19) of chronic antiarrhythmic drug therapy will likely
emper enthusiasm for this approach.
After this excellent report, it is time to define the most
ffective device system and intervention for patients with
dvanced HF and permanent AF. This study suggests that
imply inserting a CRT device will not be effective in many
f these patients, perhaps the majority—this is a major
oncern. The results of this study also beg the question of
hether all patients with advanced refractory HF and
ermanent AF should have AV ablation before CRT.
ertainly, recent data (20–22) have laid the groundwork for
ore frequent use of the “ablate and pace” approach in some
pecific clinical contexts, but to create pacemaker depen-
ency in large numbers of HF patients will require definitive
esults from a well-designed and powered randomized
linical trial.
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